论文部分内容阅读
目的研究和探讨不同眼底病患者应用玻璃体腔注射Avastin治疗的临床效果和应用价值。方法选择某院2014-01—2016-01收治的眼底病患者400例,对比治疗前后视力矫正、眼压和视网膜改变情况,以判定临床治疗效果和安全性。结果糖尿病性视网膜病变(DR)临床治疗有效率为89.83%,视网膜脉络膜新生血管(CN V)有效率为90.20%,中心性浆液性脉络膜视网膜病变(CSC)有效率为92.08%,视网膜静脉阻塞(R VO)有效率为93.33%,年龄相关性黄斑变性(ARMD)有效率88.57%,且治疗后患者视力、眼压和视网膜厚度明显改善,P<0.05,差异具有统计学意义,对比具有临床参考价值。结论玻璃体腔注射Avastin治疗眼底病患者临床效果显著,能够有效改善患者视力、眼压和视网膜厚度,抑制新生血管性病变的情况发生,是一种安全有效的治疗手段。
Objective To study and discuss the clinical effect and application value of intravitreal injection of Avastin in patients with different fundus diseases. Methods 400 cases of fundus diseases admitted to a hospital from January 2014 to June 2016 were selected to compare visual acuity, intraocular pressure and retinal changes before and after treatment to determine the clinical effect and safety. Results The effective rate of diabetic retinopathy (DR) was 89.83%, the effective rate of CNV was 90.20%, the rate of central serous chorioretinopathy (CSC) was 92.08%, the incidence of retinal vein occlusion R VO), the effective rate was 93.33%, the effective rate of age-related macular degeneration (ARMD) was 88.57%, and the visual acuity, intraocular pressure and retinal thickness were significantly improved after treatment, P <0.05, the difference was statistically significant, compared with clinical reference value. Conclusion Intravitreal injection of Avastin in the treatment of ocular fundus patients has significant clinical effect, which can effectively improve visual acuity, intraocular pressure and retinal thickness and inhibit neovascular lesions. It is a safe and effective treatment.